ELCC 2014: Lung adenocarcinoma with RET fusion: early experience with diagnosis and targeted therapy
Drs. Oliver Gautschi and Lukas Bubendorf discourse on the presence of RET aberrations in NSCLC.
Dr. Tony Mok, President of IASLC, offers an overview on most common toxicities related to targeted therapies in NSCLC.
ELCC 2014: Cabazitaxel Fails to Meet the Primary Endpoint in a Randomised Phase II Study in SCLC Patients
Cabazitaxel failed to meet a primary endpoint of showing superior progression-free survival (PFS) and additionally showed less favourable median overall survival (OS) compared to topotecan in an international, randomised open-label phase II trial performed in patients with small-cell lung cancer (SCLC), who had progressed during or after first-line platinum-based chemotherapy
ELCC 2014: Clinical Utility of miRNA Signature in Plasma of Smokers Included in LD-CT Lung Cancer Screening
A group of researchers from Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, retrospectively evaluated a non-invasive plasma miRNA signature classifier in prospectively collected samples from smokers within the randomised Multicentre Italian Lung Detection (MILD) trial.
CO-1686 has demonstrated a good tolerability and promising efficacy against T790M+ epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC).
In a large number of samples of lung adenocarcinoma the incidence of RET fusion, as detected by routine diagnostics, was higher than expected, according to a report by Dr Oliver Gautschi of the Clinic for Oncology, Kantonsspital, Luzern, Switzerland.